To add, I would say acquisitions are probably also driven a lot by how compelling the asset/s are, and not just by time. Plenty of biotechs who have to do phase 3 trials alone, and then there are some biotechs who are snapped up after Phase I. CHM's assets are clearly interesting enough to bring established professionals into a tiny Australian biotech.
I feel lucky to be in this early. IMO
Ann: CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCER, page-17
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable